Trexquant Investment LP Invests $629,000 in Atara Biotherapeutics (ATRA)

Trexquant Investment LP acquired a new stake in Atara Biotherapeutics (NASDAQ:ATRA) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 16,141 shares of the biotechnology company’s stock, valued at approximately $629,000.

Several other institutional investors also recently made changes to their positions in ATRA. Schwab Charles Investment Management Inc. raised its position in shares of Atara Biotherapeutics by 20.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 104,612 shares of the biotechnology company’s stock valued at $1,894,000 after purchasing an additional 17,995 shares during the last quarter. Alps Advisors Inc. raised its position in shares of Atara Biotherapeutics by 12.7% in the 4th quarter. Alps Advisors Inc. now owns 33,904 shares of the biotechnology company’s stock valued at $614,000 after purchasing an additional 3,809 shares during the last quarter. Pacific Heights Asset Management LLC purchased a new position in shares of Atara Biotherapeutics in the 4th quarter valued at approximately $453,000. Bank of New York Mellon Corp raised its position in shares of Atara Biotherapeutics by 4.4% in the 4th quarter. Bank of New York Mellon Corp now owns 129,237 shares of the biotechnology company’s stock valued at $2,339,000 after purchasing an additional 5,415 shares during the last quarter. Finally, Artal Group S.A. raised its position in shares of Atara Biotherapeutics by 66.7% in the 4th quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock valued at $18,100,000 after purchasing an additional 400,000 shares during the last quarter. 69.88% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics opened at $50.05 on Friday, according to Marketbeat. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $50.85.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.13). analysts forecast that Atara Biotherapeutics will post -4.06 earnings per share for the current fiscal year.

ATRA has been the subject of several research analyst reports. Jefferies Group increased their price objective on shares of Atara Biotherapeutics from $30.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, March 5th. Citigroup lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating in a research report on Thursday, February 15th. Canaccord Genuity reissued a “positive” rating and set a $70.00 price target (up from $47.00) on shares of Atara Biotherapeutics in a research report on Friday, January 19th. JPMorgan Chase began coverage on shares of Atara Biotherapeutics in a research report on Tuesday, April 10th. They set an “overweight” rating and a $56.00 price target for the company. Finally, BidaskClub raised shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $42.50.

In other news, EVP Mitchall G. Clark sold 4,647 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $46.06, for a total transaction of $214,040.82. Following the completion of the transaction, the executive vice president now directly owns 357,905 shares of the company’s stock, valued at approximately $16,485,104.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Derrell Porter sold 16,334 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $45.02, for a total transaction of $735,356.68. Following the transaction, the senior vice president now directly owns 28,834 shares of the company’s stock, valued at $1,298,106.68. The disclosure for this sale can be found here. Insiders have sold a total of 144,511 shares of company stock valued at $6,114,660 over the last three months. 10.60% of the stock is currently owned by insiders.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply